{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:18:06Z","timestamp":1788369486153,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07470-3","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:25:00Z","timestamp":1788323100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aflibercept 8\u00a0mg for diabetic macular edema and neovascular age-related macular degeneration: an italian expert consensus paper"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-9682","authenticated-orcid":false,"given":"Francesco","family":"Bandello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Midena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Eight Consensus Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"7470_CR1","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.37765\/ajmc.2023.89386","volume":"29","author":"A Almony","year":"2023","unstructured":"Almony A (2023) Treatment approaches for neovascular age-related macular degeneration and diabetic macular edema. Am J Manag Care 29:S81\u2013S89. https:\/\/doi.org\/10.37765\/ajmc.2023.89386","journal-title":"Am J Manag Care"},{"key":"7470_CR2","unstructured":"World Health Organisation (2026) Vision impairment and blindness. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment"},{"key":"7470_CR3","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Global Health"},{"key":"7470_CR4","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham Y-C, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng C-Y (2021) Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and mrta-analysis. Ophthalmology 128:1580\u20131591. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.027","journal-title":"Ophthalmology"},{"key":"7470_CR5","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.37765\/ajmc.2023.89387","volume":"29","author":"A Almony","year":"2023","unstructured":"Almony A (2023) Disease burden of neovascular age-related macular degeneration and diabetic macular edema. Am J Manag Care 29:S75\u2013S80. https:\/\/doi.org\/10.37765\/ajmc.2023.89387","journal-title":"Am J Manag Care"},{"key":"7470_CR6","unstructured":"European Medicines Agency (2026) Beovu (brolucizumab): European Public Assessment Report (EPAR) Product Information [accessed June 2026]"},{"key":"7470_CR7","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.2147\/OPTH.S532179","volume":"19","author":"K Robinson","year":"2025","unstructured":"Robinson K, Cooper SJ, Persaud S, Frederick JL, Singh RP (2025) Discordance among patients and ophthalmologists regarding the burden of intravitreal injections. Clin Ophthalmol 19:2637\u20132645. https:\/\/doi.org\/10.2147\/OPTH.S532179","journal-title":"Clin Ophthalmol"},{"key":"7470_CR8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/OPTH.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesboll C (2023) Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway. Clin Ophthalmol 17:1465\u20131474. https:\/\/doi.org\/10.2147\/OPTH.S409103","journal-title":"Clin Ophthalmol"},{"key":"7470_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S (2016) Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol 10:939\u2013946. https:\/\/doi.org\/10.2147\/OPTH.S100168","journal-title":"Clin Ophthalmol"},{"key":"7470_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R, CANDELA Study Investigators (2023) Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the Phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol 141:834\u2013842. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2421","journal-title":"JAMA Ophthalmol"},{"key":"7470_CR11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S, PHOTON Investigators (2024) Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet 403:1153\u20131163. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1","journal-title":"Lancet"},{"key":"7470_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY (2024) Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"7470_CR13","doi-asserted-by":"publisher","unstructured":"Korobelnik J-F, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY, PULSAR Investigators (2025) Intravitreal Aflibercept 8\u00a0mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial. Ophthalmology S0161\u20136420012500532. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022","DOI":"10.1016\/j.ophtha.2025.08.022"},{"key":"7470_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06847-0","author":"D Veritti","year":"2025","unstructured":"Veritti D, Sarao V, Lanzetta P (2025) Extended duration of VEGF inhibition with aflibercept 8\u00a0mg: the role of reduced ocular clearance. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-025-06847-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7470_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","volume":"11","author":"P Nasa","year":"2021","unstructured":"Nasa P, Jain R, Juneja D (2021) Delphi methodology in healthcare research: How to decide its appropriateness. World J Methodol 11:116\u2013129. https:\/\/doi.org\/10.5662\/wjm.v11.i4.116","journal-title":"World J Methodol"},{"key":"7470_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1748-5908-7-37","volume":"7","author":"J Cane","year":"2012","unstructured":"Cane J, O\u2019Connor D, Michie S (2012) Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci 7:37. https:\/\/doi.org\/10.1186\/1748-5908-7-37","journal-title":"Implement Sci"},{"key":"7470_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"6","author":"S Michie","year":"2011","unstructured":"Michie S, van Stralen MM, West R (2011) The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 6:42. https:\/\/doi.org\/10.1186\/1748-5908-6-42","journal-title":"Implement Sci"},{"key":"7470_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.10.028","author":"DV Do","year":"2025","unstructured":"Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD (2025) Intravitreal Aflibercept 8\u00a0mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2\/3 PHOTON Trial. Ophthalmol DOI. https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.028","journal-title":"Ophthalmol DOI"},{"key":"7470_CR19","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41433-024-02998-2","volume":"38","author":"CJ Payne","year":"2024","unstructured":"Payne CJ, Gupta U, Maatouk CM, Kuo BL, Perkins SW, Singh RP, Talcott KE (2024) Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema. Eye 38:1687\u20131693. https:\/\/doi.org\/10.1038\/s41433-024-02998-2","journal-title":"Eye"},{"key":"7470_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P (2023) Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med 21:133. https:\/\/doi.org\/10.1186\/s12967-023-03937-7","journal-title":"J Transl Med"},{"key":"7470_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","volume":"105","author":"V Daien","year":"2021","unstructured":"Daien V, Finger RP, Talks JS, Mitchell P, Wong TY, Sakamoto T, Eldem BM, Korobelnik J-F (2021) Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol 105:1475\u20131479. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317434","journal-title":"Br J Ophthalmol"},{"key":"7470_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, Ngah NF, Ohji M, Mitchell P, Yang C-H, Ruamviboonsuk P, Wong I, Sakamoto T, Rajendran A, Chen Y, Lam DSC, Lai C-C, Wong TY, Cheung CMG, Chang A, Koh A (2021) Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia Pac J Ophthalmol (Phila) 10:507\u2013518. https:\/\/doi.org\/10.1097\/APO.0000000000000445","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"7470_CR23","unstructured":"American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern 2026. https:\/\/www.aao.org\/education\/preferred-practice-pattern\/age-related-macular-degeneration-ppp"},{"key":"7470_CR24","unstructured":"American Academy of Ophthalmology. Diabetic retinopathy preferred practice pattern 2024. https:\/\/www.aao.org\/education\/preferred-practice-pattern\/diabetic-retinopathy-ppp"},{"key":"7470_CR25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41433-025-03627-2","volume":"39","author":"D Veritti","year":"2025","unstructured":"Veritti D, Sarao V, Lanzetta P (2025) From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD. Eye (Lond) 39:1349\u20131355. https:\/\/doi.org\/10.1038\/s41433-025-03627-2","journal-title":"Eye (Lond)"},{"key":"7470_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41433-022-02221-0","volume":"37","author":"V Chaudhary","year":"2023","unstructured":"Chaudhary V (2023) Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next? Eye 37:581\u2013583. https:\/\/doi.org\/10.1038\/s41433-022-02221-0","journal-title":"Eye"},{"key":"7470_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41433-025-04180-8","volume":"40","author":"R Gale","year":"2026","unstructured":"Gale R, Awad MH, Bailey C, Cackett P, Chhabra R, Downey L, Ghanchi F, Kotagiri A, Narendran N, Pearce I, Peto T, Sivaprasad S, Younis S, Napier J, Gilbert R, Ismat S (2026) Aflibercept 8\u00a0mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel. Eye (Lond) 40:959\u2013965. https:\/\/doi.org\/10.1038\/s41433-025-04180-8","journal-title":"Eye (Lond)"},{"key":"7470_CR28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s40123-025-01140-z","volume":"14","author":"M Shellvarajah","year":"2025","unstructured":"Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D (2025) Adherence to anti-VEGF treatment in patients with neovascular age-related macular degeneration: a real-world study. Ophthalmol Ther 14:1261\u20131269. https:\/\/doi.org\/10.1007\/s40123-025-01140-z","journal-title":"Ophthalmol Ther"},{"key":"7470_CR29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41433-020-01309-9","volume":"35","author":"M Iglicki","year":"2021","unstructured":"Iglicki M, Gonzalez DP, Loewenstein A, Zur D (2021) Longer-acting treatments for neovascular age-related macular degeneration-present and future. Eye (Lond) 35:1111\u20131116. https:\/\/doi.org\/10.1038\/s41433-020-01309-9","journal-title":"Eye (Lond)"},{"key":"7470_CR30","unstructured":"The Royal College of Ophthalmologists (2024) Commissioning guidance. Age-related macular degeneration services: evidence base. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/08\/AMD-Commissioning-Guidance-Evidence-Base-2024.pdf"},{"key":"7470_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/ICU.0000000000001129","volume":"36","author":"M Kalavar","year":"2025","unstructured":"Kalavar M, Sridhar J (2025) Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol 36:189\u2013198. https:\/\/doi.org\/10.1097\/ICU.0000000000001129","journal-title":"Curr Opin Ophthalmol"},{"key":"7470_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajo.2021.12.005","volume":"237","author":"M Bouaziz","year":"2022","unstructured":"Bouaziz M, Cheng T, Minuti A, Denisova K, Barmettler A (2022) Shared decision making in ophthalmology: a scoping review. Am J Ophthalmol 237:146\u2013153. https:\/\/doi.org\/10.1016\/j.ajo.2021.12.005","journal-title":"Am J Ophthalmol"},{"key":"7470_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005656.pub3","volume":"11","author":"T Rittiphairoj","year":"2020","unstructured":"Rittiphairoj T, Mir TA, Li T, Virgili G (2020) Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 11:CD005656. https:\/\/doi.org\/10.1002\/14651858.CD005656.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"7470_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaophthalmol.2023.2098","volume":"141","author":"S Zafar","year":"2023","unstructured":"Zafar S, Walder A, Virani S, Biggerstaff K, Orengo-Nania S, Chang J, Channa R (2023) Systemic adverse events among patients with diabetes treated with intravitreal anti\u2013vascular endothelial growth factor injections. JAMA Ophthalmol 141:658\u2013666. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2098","journal-title":"JAMA Ophthalmol"},{"key":"7470_CR35","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1038\/s41433-024-03312-w","volume":"38","author":"J-F Korobelnik","year":"2024","unstructured":"Korobelnik J-F, Lanzetta P, Wykoff CC, Wong TY, Zhang X, Morgan-Warren P, Fitzpatrick S, Leal S, Brunck L, Hasanbasic Z, Chu KW, Reed K, Sivaprasad S (2024) Sustained disease control with aflibercept 8\u00a0mg: a new benchmark in the management of retinal neovascular diseases. Eye 38:3218\u20133221. https:\/\/doi.org\/10.1038\/s41433-024-03312-w","journal-title":"Eye"},{"key":"7470_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Gentile B, Chi GC, Mirt M, Kosmas CE, Lambert J, Lanar S, Lewis HB, Holekamp NM (2022) Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence 16:587\u2013604. https:\/\/doi.org\/10.2147\/PPA.S347713","journal-title":"Patient Prefer Adherence"},{"key":"7470_CR37","doi-asserted-by":"publisher","unstructured":"Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL (2018) Optimizing anti-VEGF treatment outcomes for patients with Neovascular age-related macular degeneration. J Manag Care Spec Pharm 24 (Number 2-a Suppl). https:\/\/doi.org\/10.18553\/jmcp.2018.24.2-a.s3","DOI":"10.18553\/jmcp.2018.24.2-a.s3"},{"key":"7470_CR38","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41433-020-0799-y","volume":"34","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A (2020) Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye 34:2249\u20132256. https:\/\/doi.org\/10.1038\/s41433-020-0799-y","journal-title":"Eye"},{"key":"7470_CR39","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, Best C, Sagkriotis A (2021) Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond) 35:2983\u20132990. https:\/\/doi.org\/10.1038\/s41433-020-01354-4","journal-title":"Eye (Lond)"},{"key":"7470_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40123-025-01098-y","volume":"14","author":"P Wojciechowski","year":"2025","unstructured":"Wojciechowski P, Wdowiak M, Panek M, Lunk I, Carrasco J, Zhang X, Wu O, Korobelnik J-F, Lanzetta P (2025) Efficacy, safety, and injection frequency with novel aflibercept 8 mg in neovascular age-related macular degeneration: a comparison with existing anti-VEGF regimens using a Bayesian network meta-analysis. Ophthalmol Ther 14:733\u2013753. https:\/\/doi.org\/10.1007\/s40123-025-01098-y","journal-title":"Ophthalmol Ther"},{"key":"7470_CR41","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41433-025-03765-7","volume":"39","author":"V Sarao","year":"2025","unstructured":"Sarao V, Veritti D, Bonini F, Martin AA, Lanzetta P (2025) Early intraocular pressure dynamics following aflibercept 8\u00a0mg versus aflibercept 2\u00a0mg: a propensity score-matched analysis. Eye 39:1933\u20131939. https:\/\/doi.org\/10.1038\/s41433-025-03765-7","journal-title":"Eye"},{"key":"7470_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-326053","author":"A Paris","year":"2024","unstructured":"Paris A, Volpe G, Perruchoud-Ader K, Casanova A, Menghini M, Grimaldi G (2024) Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjo-2024-326053","journal-title":"Br J Ophthalmol"},{"key":"7470_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12886-025-04111-x","volume":"25","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang T, Zhang X, Li M, Han L, Lan X, Wang L, Wang X (2025) Contributing factors to short-term intraocular pressure elevation following intravitreal anti-VEGF injections. BMC Ophthalmol 25:281. https:\/\/doi.org\/10.1186\/s12886-025-04111-x","journal-title":"BMC Ophthalmol"},{"key":"7470_CR44","doi-asserted-by":"publisher","first-page":"e934","DOI":"10.1016\/j.jcjo.2025.06.003","volume":"60","author":"M Zaman","year":"2025","unstructured":"Zaman M, Alowedi S, Sharma S (2025) Anterior chamber paracentesis for increased intraocular pressure with intravitreal injections: systematic review and meta-analysis. Can J Ophthalmol 60:e934\u2013e945. https:\/\/doi.org\/10.1016\/j.jcjo.2025.06.003","journal-title":"Can J Ophthalmol"},{"key":"7470_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","volume":"143","author":"KE Binder","year":"2025","unstructured":"Binder KE, Bleidi\u00dfel N, Charbel Issa P, Maier M, Coulibaly LM (2025) Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. JAMA Ophthalmol 143:499\u2013506. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.0969","journal-title":"JAMA Ophthalmol"},{"key":"7470_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/vision10020018","author":"M Prasad","year":"2026","unstructured":"Prasad M, Ramsey DJ (2026) Adverse events reported with standard-dose and high-dose aflibercept: a FAERS pharmacovigilance study. Vision (Basel). https:\/\/doi.org\/10.3390\/vision10020018","journal-title":"Vision (Basel)"},{"key":"7470_CR47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/life15060903","volume":"15","author":"M Musadiq","year":"2025","unstructured":"Musadiq M, Musadiq M, Latif F, Ng B, Azzopardi M, Gilead N, Needham A, Chong YJ (2025) Early real-world outcomes of switching to 8\u00a0mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life 15:903. https:\/\/doi.org\/10.3390\/life15060903","journal-title":"Life"},{"key":"7470_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00665-6","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM (2025) Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-na\u00efve neovascular AMD: AI-assisted fluid volume analysis. Int J Retina Vitreous 11:42. https:\/\/doi.org\/10.1186\/s40942-025-00665-6","journal-title":"Int J Retina Vitreous"},{"key":"7470_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020350","volume":"16","author":"M Santorsola","year":"2024","unstructured":"Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G, Vanni G, Maiolino P, Correra M, Granata V, Gualillo O, Berretta M, Ottaiano A (2024) Exploring the spectrum of VEGF inhibitors\u2019 toxicities from systemic to intravitreal usage in medical practice. Cancers 16:350. https:\/\/doi.org\/10.3390\/cancers16020350","journal-title":"Cancers"},{"key":"7470_CR50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/24741264211028441","volume":"5","author":"LA Lam","year":"2021","unstructured":"Lam LA, Mehta S, Lad EM, Emerson GG, Jumper JM, Awh CC, Task Force on Intravitreal Injection Supplemental S (2021) Intravitreal injection therapy: current techniques and supplemental services. J Vitreoretin Dis 5:438\u2013447. https:\/\/doi.org\/10.1177\/24741264211028441","journal-title":"J Vitreoretin Dis"},{"key":"7470_CR51","unstructured":"Oxford Centre of Evidence-Based Medicine. OCEBM levels of evidence. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07470-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:02:46Z","timestamp":1788368566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07470-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":51,"alternative-id":["7470"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07470-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not required as this research did not involve human subjects or animals.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco Bandello\n                      : Consultant for Abbvie, Adverum Biotechnologies, Alimera, Apellis, Bayer, Boehringer Ingelheim, Breye Therapeutics Aps, Fidia Sooft, Hoffmann-La Roche, Outlook Therapeutics, Novartis, NTC Pharma, Oxurion NV, 4D Molecular Therapeutics, SIFI.\n                      Enrico Borrelli\n                      : Member of the Editorial Board of Graefe's Archive for Clinical and Experimental Ophthalmology, not involved in peer review or editorial decisions for this manuscript. Funding from Bayer, Roche, Abbvie and Zeiss.\n                      Sandro De Falco\n                      : Consultant for Bayer.\n                      Alessandro Invernizzi\n                      : Consultant for Bayer, Novartis, Roche, AbbVie, Heidelberg Engineering.\n                      Paolo Lanzetta\n                      : Consultant for 4DMT, AbbVie, Adverum, Annexon, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, Celltrion, EyePoint, I-Care, Genentech, MSD, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche.\n                      Marco Lupidi\n                      : Financial interest in Abbvie, Bayer, Heidelberg Engineering, Roche.\n                      Edoardo Midena\n                      : No competing interests.\n                      Federico Ricci\n                      : No competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}